What's Happening?
VenstraMedical, a cardiovascular medical device company, has secured investment from Highcroft Capital, a Minnesota-based venture capital firm specializing in MedTech innovation. This funding aims to accelerate
the development of VenstraMedical's next-generation percutaneous ventricular assist device (pVAD), designed to provide complete ventricular unloading for patients in cardiogenic shock or undergoing high-risk coronary interventions. The pVAD is a catheter-based pump protected by eight issued patents, capable of delivering up to 7 L/min of cardiac output once deployed. The investment follows the publication of VenstraMedical's pre-clinical data and a $1 million grant from MTPConnect's Targeted Translation Research Accelerator.
Why It's Important?
The investment from Highcroft Capital is significant as it supports the advancement of VenstraMedical's innovative cardiac support device, which could transform cardiac care through improved performance, safety, and ease of use. The global market for percutaneous ventricular assist devices (pVADs) exceeds $2 billion annually and is rapidly growing, indicating a strong demand for effective cardiac support solutions. This development could lead to improved patient outcomes and potentially set new standards in temporary mechanical circulatory support, benefiting both healthcare providers and patients.
